Visceral Metastasis Predicts Response to New Hormonal Agents in Metastatic Castration-Sensitive Prostate Cancer

Creative Commons License

Yekeduz E., McKay R. R., Gillessen S., Choueiri T. K., ÜRÜN Y.

ONCOLOGIST, cilt.28, sa.7, ss.596-603, 2023 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Derleme
  • Cilt numarası: 28 Sayı: 7
  • Basım Tarihi: 2023
  • Doi Numarası: 10.1093/oncolo/oyad102
  • Dergi Adı: ONCOLOGIST
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, CINAHL, EMBASE, MEDLINE, Directory of Open Access Journals
  • Sayfa Sayıları: ss.596-603
  • Anahtar Kelimeler: prostate cancer, castration-sensitive, abiraterone acetate, non-steroidal anti-androgens, ANDROGEN, ENZALUTAMIDE, SURVIVAL, THERAPY, MANAGEMENT, RESISTANCE, DOCETAXEL, MECHANISM, LIVER
  • Ankara Üniversitesi Adresli: Evet

Özet

This review evaluates the pooled data from phase III trials of androgen-receptor signaling inhibitors in patients with metastatic castration-sensitive prostate cancer to dissect the impact of abiraterone acetate plus prednisone versus non-steroidal anti-androgens on overall survival for metastatic castration-sensitive prostate cancer with visceral metastasis.